Key result
Higher-dose rivastigmine improves cognitive function in Alzheimer's disease, but missing trial data limits reliability.
Why the study?
Does rivastigmine improve cognitive outcomes in patients with Alzheimer's disease?
Systematic Review (n=3,370)
Double-blind
Randomized
Does rivastigmine improve cognitive outcomes in patients with Alzheimer's disease?
Odds Ratio: 0.32 (95% CI 0.18–0.59)
Rivastigmine may offer cognitive benefits for patients with Alzheimer's disease.
Review: rivastigmine may improve cognitive outcomes in Alzheimer's diseaseBirks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
R. Morris Bullock (2000) conducted a systematic review in Alzheimer's disease (n=3,370). Rivastigmine vs. Placebo was evaluated on Improvement in cognitive function (>4 points improvement on the cognitive subscale of the Alzheimer's Disease Assessment Scale [ADAS-Cog]) (OR 0.32, 95% CI 0.18 to 0.59). Higher dose rivastigmine significantly improved cognitive function compared to placebo (OR 0.32) in patients with Alzheimer's disease, though missing data from unpublished trials limits reliability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: